In addition to being the world’s first Placenta•Cord™ banking company, LifebankUSA™ is committed to being at the forefront of research and development to help ensure a more promising future for both placental and umbilical cord blood stem cell therapeutics. Together with our parent company Celgene®, we’ve developed collaborations with some of the country’s premier medical centers to advance therapies in areas such as heart disease, cancer, neurodegenerative diseases such as ALS (Lou Gehrig’s disease), and spinal cord injury.
The Proof is in Our Collaborations
|
Stem Cell Expansion TechnologyLifebankUSA is committed to developing new technologies to advance the possibilities of stem cell therapeutics. Currently, one of the parameters affecting successful stem cell engraftment is the stem cell dose given to the client. In order to improve engraftment, LifebankUSA is actively researching different technologies to expand the number of stem cells available for transplantation. |
LifebankUSA™, A Celgene Company. Copyright © 2007